These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20178438)

  • 1. E-mail and photographs: a case report of a patient-initiated diagnostic tool in the era of electronic communication.
    Hartgers M; Jatoi A
    J Palliat Med; 2010 Mar; 13(3):335-7. PubMed ID: 20178438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trials.
    Solomon BM; Jatoi A
    J Palliat Med; 2011 Feb; 14(2):153-6. PubMed ID: 21226620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Mediation-and Antiandrogens Mitigation-of the Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series.
    Le-Rademacher JG; Rowland K; Atherton PJ; Dakhil C; Sun Z; Tan A; Schmidt L; Nguyen PL; Radecki Breitkopf C; Pittelkow M; Tindall D; Menon S; Jatoi A
    Am J Hosp Palliat Care; 2019 Jun; 36(6):519-525. PubMed ID: 30602311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rash from EGFR inhibitors: opportunities and challenges for palliation.
    Solomon BM; Jatoi A
    Curr Oncol Rep; 2008 Jul; 10(4):304-8. PubMed ID: 18778556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan
    Chen L; Brown J; Marmaduke DQ; Mayo C; Grau G; Lau YK; Obasaju CK
    Support Care Cancer; 2018 Jul; 26(7):2369-2377. PubMed ID: 29423677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy: An updated meta-analysis of 23 randomized controlled trials.
    Chen ZQ; Li ZY; Yang CZ; Lin RT; Lin LZ; Sun LL
    Complement Ther Med; 2019 Dec; 47():102167. PubMed ID: 31780021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
    Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
    Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A qualitative study of the ramifications of rash from epidermal growth factor receptor (EGFR) inhibitors.
    Coleman S; Kovtun I; Nguyen PL; Pittelkow M; Jatoi A
    Psychooncology; 2011 Nov; 20(11):1246-9. PubMed ID: 20865737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case of Lenalidomide-Associated Papulopustular Rash: Beyond the Epidermal Growth Factor Receptor Inhibitor Spectrum.
    Fernandez-Nieto D; Ortega-Quijano D; Jimenez-Cauhe J; Saceda-Corralo D; Bea-Ardebol S
    Am J Ther; 2020; 27(4):e417-e419. PubMed ID: 32618603
    [No Abstract]   [Full Text] [Related]  

  • 11. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
    Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
    Sun W; Li J
    Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
    Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
    Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
    Tohyama M; Hamada M; Harada D; Kozuki T; Nogami N; Monden N; Kajiwara T; Nishina T
    J Dermatol; 2020 Feb; 47(2):121-127. PubMed ID: 31803963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
    Chou LS; Garey J; Oishi K; Kim E
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Don't jump to rash conclusions.
    Bebb G; Boland W; Melosky B
    Cancer Biol Ther; 2011 Apr; 11(7):639-41. PubMed ID: 21304273
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between epidermal growth factor receptor mutations and skin rash in non-small cell lung cancer patients.
    Tanaka H; Atagi K; Tatsumichi T; Yamaguchi K; Takahashi K; Kaji M; Kosaka S; Houchi H
    J Chemother; 2020 Apr; 32(2):83-87. PubMed ID: 31957595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.
    Wong SF; Lindgren A; Mummaneni M; Byun T; Vasko C; Arenos R; Alexson E; Osann K
    J Support Oncol; 2010; 8(5):202-8. PubMed ID: 21086877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
    Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
    Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.